drugset / Trial / NCT01015014

Safety, Pharmacokinetics (PK) and Tolerability Study of a Novel Drug for Treatment of Bacterial Infections

NCT01015014

Phase 1 Completed 64 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetic profile of an antibacterial compound for treatment of hospital acquired Gram negative infection.

Timeline

Start
2009-11-05
Primary completion
2010-05-13
Completion
2010-05-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Epetraborole Small molecule 600 mg